First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

Heinz-Josef Lenz Eric Van Cutsem Maria Luisa LimonKa Yeung Mark WongAlain Hendlisz Massimo AgliettaPilar García-AlfonsoBart NeynsGabriele LuppiDana Backlund CardinTomislav DragovichUsman ShahSandzhar AbdullaevJoseph GricarJean-Marie LedeineMichael James Overman Sara Lonardi

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.

Keyphrases

phase ii
low dose
open label
metastatic colorectal cancer
clinical trial
double blind
placebo controlled
high dose
phase iii
big data
randomized controlled trial
machine learning
study protocol
artificial intelligence